Excuse our skepticism about the military (and in doing the work, pharmaceutical companies) getting involved in wanting to improve how psychedelics might be used in psychotherapy.
We remember Marinol (still being used), and more recently a CBD drug which is basically CBD and costs patients something like $33,000 a year, but we also remember covert, highly unethical research done on psychedelics and US citizens between the 1950s and 1970s by the military and US intelligence agencies.
That said, the use of psychedelics in therapy is already on the road to becoming mainstream, and depending on how research is managed can become very useful to a much larger number of people down the road to than today.
The successful use of controlled substances such as ketamine and psilocybin mushrooms to treat mental health issues like depression and anxiety has ushered in a new era of interest in psychedelic drugs. But for researchers and clinicians eager to expand such therapies, an obvious question remains: D…